Abstract

Combating the social and economic consequences of a growing elderly population will require the identification of interventions that slow the development of age-related diseases. Preserved cellular homeostasis and delayed aging have been previously linked to reduced cell proliferation and protein synthesis rates. To determine whether changes in these processes may contribute to or predict delayed aging in mammals, we measured cell proliferation rates and the synthesis and replacement rates (RRs) of over a hundred hepatic proteins invivo in three different mouse models of extended maximum lifespan (maxLS): Snell Dwarf, calorie-restricted (CR), and rapamycin (Rapa)-treated mice. Cell proliferation rates were not consistently reduced across the models. In contrast, reduced hepatic protein RRs (longer half-lives) were observed in all three models compared to controls. Intriguingly, the degree of mean hepatic protein RR reduction was significantly correlated with the degree of maxLS extension across the models and across different Rapa doses. Absolute rates of hepatic protein synthesis were reduced in Snell Dwarf and CR, but not Rapa-treated mice. Hepatic chaperone levels were unchanged or reduced and glutathione S-transferase synthesis was preserved or increased in all three models, suggesting a reduced demand for protein renewal, possibly due to reduced levels of unfolded or damaged proteins. These data demonstrate that maxLS extension in mammals is associated with improved hepatic proteome homeostasis, as reflected by a reduced demand for protein renewal, and that reduced hepatic protein RRs hold promise as an early biomarker and potential target for interventions that delay aging in mammals.

Highlights

  • Age is a risk factor for numerous diseases including cancer, diabetes, and neurodegenerative diseases (Miller, 2002)

  • There was no difference in the proliferation rates of epidermal cells in Snell Dwarf compared to Het/ WT mice (Fig. 1A)

  • By comparing the 54 proteins for which we derived replacement rates (RRs) data in all three models, we found a significant correlation between the degree of maximum lifespan (maxLS) extension and the degree of hepatic protein RR reduction

Read more

Summary

Introduction

Age is a risk factor for numerous diseases including cancer, diabetes, and neurodegenerative diseases (Miller, 2002). The extension of maximum lifespan (maxLS, generally defined as the age at which 90% of individuals in a given population have died) has proven to be a useful outcome metric, as it in principle represents a general slowing of the aging process rather than the curing of one specific age-related disease. Over the last 50 years, several dietary, genetic, and pharmacological interventions have been identified that extend maxLS in laboratory animals, including mice (Weindruch et al, 1986; Liang et al, 2003; Miller et al, 2005; Harrison et al, 2009, 2014). Identifying metrics of biological processes, or biomarkers (BMs), that are involved in the slowing of aging in laboratory mammals will be essential for guiding the future development of interventions to extend human healthspan

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call